HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

FDA grants Breakthrough Therapy Designation to psilocybin program for major depressive disorder

by admin | Nov 25, 2019 | FDA

Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatmentof major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Azitra Bioeq Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Distribution Drug Discovery Enterome EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies Licensing M&A medical device microbiome Neuro next-gen sequencing PathAI pathology Pepticom pharma RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

 contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.